CERo Therapeutics issued a convertible promissory note to SRX Health Solutions, Inc. for a purchase price of $750,000. The note carries a principal face value of $937,500. The debt bears an annual interest rate of 10% and matures on May 28, 2027. The lender has the option to convert the principal and interest into common stock at a price equal to the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over the 20 days prior to conversion. The company is obligated to file a registration statement for the resale of shares issuable upon conversion.